December 11, 2019
The Ministry of Health, Labor and Welfare (MHLW) on December 10 granted orphan drug designation for additional indications being developed for two IL-17A inhibitors, Novartis Pharma’s Cosentyx (secukinumab) and Kyowa Kirin’s Lumicef (brodalumab). The designation was given for Cosentyx for...read more